Gemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Xiaoyu Liu, Xuerong Yang, Guofeng Zhou, Yi Chen, Changyu Li, Xiaolin Wang, Xiaoyu Liu, Xuerong Yang, Guofeng Zhou, Yi Chen, Changyu Li, Xiaolin Wang

Abstract

The present study was carried out to investigate the prognostic factors in patients who received intra-arterial infusion for advanced pancreatic cancer. In addition, the detailed procedure of intra-arterial infusion chemotherapy was described. A total of 354 patients with advanced unresectable pancreatic adenocarcinoma were recruited from January 2012, to April 2015, at Zhongshan Hospital Fudan University, Shanghai, China. Demographic and clinic characteristics of the patients were extracted from electronic medical records. Restricted cubic spline was used to assess the nonliner regression between baseline CA19-9 value and overall survival. Kaplan-Meier analysis and Cox proportional hazard models were used to estimate the association between overall survival and clinical characteristics. Of all 354 included patients, 230 (65%) were male (male/female ratio = 1.8), and 72 (20%) patients were diagnosed with detectable distant metastases. Pretreatment CA19-9 value of patients with metastases was significantly higher as compared to those with locally advanced cancer (median: 922.30 vs 357.00 U/mL, P = 0.0090). Totally 274 patients completed 1 cycle of intra-arterial infusion, whereas 80 patients received 2 or more cycles of the chemotherapy. For all the 354 patients, median OS was 7.0 months (95% CI: 6.0, 8.0 months) with a 6-, 12-, and 18-month survival rate of 0.48, 0.28, and 0.18, respectively. The median OS of patients, who received 1 cycle of intra-arterial infusion therapy, was 6.0 months (95% CI: 5.0, 8.0 months), which was similar to 7.0 months (95% CI: 6.0, 9.0 months) in patients who received 2 or more cycles. Restricted cubic spline revealed the nonline association between baseline CA19-9 and prognosis. The Cox proportional hazard model showed that age, CA19-9 baseline, CA19-9 value, and tumor location were significantly associated with the OS. In conclusion, the gemcitabine-based RIAC presented a potential treatment method for advanced pancreatic adenocarcinoma. Young age, pretreatment CA19-9 value <1000 U/mL, and tumor located at the head of pancreas indicated better response to the regional intra-arterial chemotherapy and better overall survival.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
(A) The tumor feeding vessel was the splenic artery. (B) The tumor-supplying arteries were arising from the celiac artery. (C) Supermesenteric artery participated in the blood supply. (D) Blood-supplying artery was catheterized super selectively.
FIGURE 2
FIGURE 2
Nonliner association between pretreatment CA19-9 value and prognosis of all patients.
FIGURE 3
FIGURE 3
(A) Association between the pretreatment CA19-9 level and overall survival. (B) Association between post-treatment change of CA19-9 value and overall survival.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65:5–29.
    1. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369:1691–1703.
    1. Long J, Luo G-p, Xiao Z-w, et al. Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China. Cancer Lett 2014; 346:273–277.
    1. Sadeghi N, Abbruzzese JL, Yeung S-CJ, et al. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012; 18:2905–2912.
    1. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817–1825.
    1. Paniccia A, Hosokawa P, Henderson W, et al. Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma. JAMA Surg 2015; 150:701–710.
    1. Chen T, Zhang M-G, Xu H-X, et al. Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma. Medicine 2015; 94:e751.
    1. Sultana A, Smith CT, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25:2607–2615.
    1. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960–1966.
    1. Frese KK, Neesse A, Cook N, et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2012; 2:260–269.
    1. Liu F, Tang Y, Sun J, et al. Regional intra-arterial vs. systemic chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis of randomized controlled trials. PloS One 2012; 7:e40847.
    1. Shi S, Yao W, Xu J, et al. Combinational therapy: new hope for pancreatic cancer? Cancer Lett 2012; 317:127–135.
    1. Ohigashi H, Ishikawa O, Imaoka S, et al. A new method of intra-arterial regional chemotherapy with more selective drug delivery for locally advanced pancreatic cancer. Hepatogastroenterology 1995; 43:338–345.
    1. Cantore M, Pederzoli P, Cornalba G, et al. Intra-arterial chemotherapy for unresectable pancreatic cancer. Ann Oncol 2000; 11:569–573.
    1. Tanaka T, Sho M, Nishiofuku H, et al. Unresectable pancreatic cancer: arterial embolization to achieve a single blood supply for intraarterial infusion of 5-fluorouracil and full-dose IV gemcitabine. Am J Roentgenol 2012; 198:1445–1452.
    1. Sobin Leslie H., Gospodarowicz Mary K., Christian Wittekind. TNM classification of malignant tumours[M]. John Wiley & Sons, 2011.
    1. Jalanko H, Kuusela P, Roberts P, et al. Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol 1984; 37:218–222.
    1. Heinzl H, Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed 1997; 54:201–208.
    1. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med 2010; 29:1037–1057.
    1. Hong K, Khwaja A, Liapi E, et al. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006; 12:2563–2567.
    1. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039–2048.
    1. Bertelli E, Di Gregorio F, Bertelli L, et al. The arterial blood supply of the pancreas: a review. Surg Radiol Anat 1996; 18:1–9.
    1. Takamori H, Kanemitsu K, Tsuji T, et al. 5-Fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer. Pancreas 2005; 30:223–226.
    1. Mambrini A, Sanguinetti F, Pacetti P, et al. Intra-arterial infusion of 5-fluorouracil, leucovorin, epirubicin and carboplatin (FLEC regimen) in unresectable pancreatic cancer: results of a ten-year experience. In Vivo 2006; 20 (6A):751–755.
    1. Muchmore JH, Carter RD, Preslan JE, et al. Regional chemotherapy with hemofiltration: a rationale for a different treatment approach to advanced pancreatic cancer. Hepatogastroenterology 1995; 43:346–355.
    1. Arredondo MA, Chaudhuri B, Kar R, et al. Isolated perfusion of pancreas with mitomycin C. Am J Surg 1990; 159:569–574.
    1. Partyka K, Maupin KA, Brand RE, et al. Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation. Proteomics 2012; 12:2212–2220.
    1. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003; 138:951–955.discussion 955–956.
    1. Zhang JJ, Zhu Y, Zhu Y, et al. Association of increased DNA methyltransferase expression with carcinogenesis and poor prognosis in pancreatic ductal adenocarcinoma. Clin Translat Oncol 2012; 14:116–124.
    1. Micke O, Bruns F, Schafer U, et al. CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res 2003; 23 (2a):835–840.
    1. Gogas H, Lofts FJ, Evans TR, et al. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer 1998; 77:325–328.
    1. Heinemann V, Schermuly MM, Stieber P, et al. CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin. Anticancer Res 1999; 19 (4a):2433–2435.
    1. Yang X, Hao J, Zhu C-H, et al. Survival benefits of Western and traditional Chinese medicine treatment for patients with pancreatic cancer. Medicine 2015; 94 26:

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner